
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 1, Issue 4 325-330, Copyright © 1992 by American Association for Cancer Research
ARTICLES |
JA Tangrea, ME Adrianza and WE Helsel
Cancer Prevention Studies Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892.
The perceptions of patients regarding the benefits, disadvantages, and importance of their participation in a long-term cancer chemoprevention trial, the Isotretinoin-Basal Cell Carcinoma Prevention Trial, were assessed through a questionnaire mailed at the conclusion of the 3-year treatment period of the trial. Responses were evaluated overall, as well as within subgroups defined by sex, age, education level, treatment group, presence of side effects, and the number of skin biopsies performed during the 3-year intervention phase. Overall, "careful medical follow-up received" (43%) and "being part of a research effort" (24%) were the most frequently cited important benefits, while the "amount of time taken to attend clinic" (32%) and "side effects" (20%) were the most frequently cited unpleasant aspects of trial participation. Most surveyed patients viewed the study as "very or extremely important" to their general health (62%) and their skin cancer condition (88%) and, as a result of participation, felt "much or somewhat better" physically (52%). The majority indicated that they would "definitely or probably" be willing to take part in another research study (79%) and take the study medication, if it were shown to be effective in the trial (78%). Overall and subgroup data provide important insights into patient motivations and attitudes regarding cancer chemoprevention trial participation, adherence, and satisfaction.
This article has been cited by other articles:
![]() |
C. T. Veit A Single Mathematical Model Predicts Physicians' Recommendations and Postmenopausal Women's Decisions to Participate in a Clinical Trial to Prevent Breast Cancer or Coronary Heart Disease Med Decis Making, August 1, 2004; 24(4): 330 - 350. [Abstract] [PDF] |
||||
![]() |
D. A. Sample, P. S. Sinicrope, M. J. Wargovich, and F. A. Sinicrope Post-Study Aspirin Intake and Factors Motivating Participation in a Colorectal Cancer Chemoprevention Trial Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 281 - 285. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |